GILEAD SCIENCES, INC. (GILD) Form 10-Q — Aug 6, 2026

$GILDForm 10-QFiled Aug 6, 2026, 4:13 PM ET0000882095-26-000031Original filing

Gilead reported Q2 2026 total revenues of $7.8 billion, up 10% year over year, but posted a net loss of $10.5 billion and diluted loss per share of $8.45 versus net income of $2.0 billion a year ago. The swing was driven by $11.2 billion of acquired IPR&D charges from the Arcellx, Tubulis and Ouro Medicines acquisitions plus a $1.75 billion IPR&D impairment on assets previously acquired from Immunomedics. During the quarter Gilead closed acquisitions of Arcellx for roughly $6.4 billion, Tubulis for about $3.2 billion and Ouro Medicines for approximately $1.9 billion, funded in part by $3.0 billion of new senior notes and a $1.1 billion term loan draw.

Key figures

Revenue: 7803000000
Total Debt: 26246000000
Revenue Yoy: 10%
Total Assets: 49362000000
Cash Position: 3179000000
Shares Outstanding: 1239955155
Descovy q2: $967M (+48%)
Veklury q2: $23M (-81%)
Yeztugo q2: $232M
Biktarvy q2: $3,772M (+7%)
Q2 buybacks: $355M (3M shares at $131.83 avg)
Trodelvy q2: $457M (+26%)
Hiv sales q2: $5,693M (+12%)
Cell therapy q2: $417M (-14%)
Term loan drawn: $1.1B under a $4.7B one-year facility
Six month revenue: $14,763M (+7%)
Iprd impairment q2: $1.75B (Immunomedics-acquired assets)
Quarterly dividend: $0.82 per share
Six month net loss: $(8,475)M
Arcellx acquisition: $6.4B cash net of cash acquired, plus CVR of $5/share (~$300M total)
Tubulis acquisition: $3.2B cash net of cash acquired, plus up to $1.9B milestones
Product sales q2 2026: $7,627M (+8%)
Six month diluted eps: $(6.82)
Lakefront upfront share: $860M recorded as reduction of IPR&D expense
Notes repaid march 2026: $2.75B
Product gross margin q2: 79.3%
Acquired iprd expense q2: $11,183M
Ouro medicines acquisition: $1.9B aggregate ($1.6B cash + contingent consideration up to $500M)
Senior notes issued may 2026: $3.0B across four tranches (4.25%-4.90%)
Operating cash flow six months: $6,117M vs $2,584M prior year

Price after filing

1 day: -2.6%7 days: +2.1%30 days: +11.6%

Close on the filing date to close N calendar days later (from $135.25). Historical, not a forecast.

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.